



Study DE007
Dosing every week



Study DE009
Dosing every other week

FIGURE 1




ACR 20/50/70 Response
at 24 Weeks
70
60
50
40
30
20
10
0
14.5
49.3
65.7
65.7
Placebo
20 mg
40 mg
80 mg
ACR20
ACR50
ACR70

FIGURE 2

A


Course of Tender Joint Count over 24 Weeks
Placebo
20 mg
40 mg
80 mg
% Improvement in TJC
70
60
50
40
30
20
10
0
0
5
10
15
20
Time (weeks)

B



Course of Swollen Joint Count over 24 Weeks
Placebo
20 mg
40 mg
80 mg
% Improvement in SJC
70
60
50
40
30
20
10
0
-1
4
9
14
19
24
Time (weeks)

FIGURE 3

SF-36 SCALE




FIGURE 4




FIGURE 4

Percentage of ACR20 responders following a single i.v. injection of D2E7 and/or placebo (DE010)




FIGURE 5